Giant Congenital Melanocytic Nevus (GCMN) - A New Hope for Targeted Therapy?
Keywords:nevi, congenital nevi, dermabrasion, surgery, NRAS, targeted therapy
AbstractWe present a 6-month-old male patient, who was consulted with dermatologist by his parents, because of a pigmented lesion, present since birth, covering almost the all skin of the back and buttocks.Â A sharply bordered, unequally coloured congenital pigmented nevus, measuring approximately 21 cm in diameter was observed in the whole body skin examination. The lesion was affecting the lower 2/3 of the skin of the back and the top half of the gluteus area, extending to the lateral part of the tors, forward the abdomen and the upper lateral part of the hips, composed by multiple darker-pigmented nests and several lighter areas, with single depigmented zones, hairy surface, irregularly infiltrated on palpation. Congenital melanocytic nevi are presented in approximately 1% of newborns, while giant congenital melanocytic nevi (GCMN) are the most uncommon subtype of them; with occurrence rate 1 in 50,000 births. They affect 2% of a total body surface or presenting in a diameter larger than 20 cm in older children. Although not common, the possible malignant transformation remains one of the most important considerations related to them, as the related lifetime risk of melanoma is 4% to 10%. Treatment recommendations include non-surgical methods as dermabrasion only within the first two weeks of life, for prevention the possible melanocytic deeper migration, while serial surgical excisions or tissue expanders could be useful treatment tool even in later stages. Nevertheless, cosmetic result is not always satisfactory, and the risk of malignant changes remains, in cases of previous melanocytic migration in deeper layer. Recent article suggests the potential role in the treatment of GCMN with NRAS inhibitor trametinib, approved for treatment of advanced melanoma, associated with underlying NRAS mutations. Although promising, the drug could be useful in paediatric patients, only with associated NRAS gene mutation. It is still unclear whether it could be helpful, independent of the NRAS status.
Plum Analytics Artifact Widget Block
Ma T, Fan K, Li L, Xie F, Li H, Chou H, Zhang Z. Tissue expansion in the treatment of giant congenital melanocytic nevi of the upper extremity. Medicine (Baltimore). 2017; 96(13):e6358. https://doi.org/10.1097/MD.0000000000006358 PMid:28353563 PMCid:PMC5380247
Kopf AW, Bart RS, Hennessey P. Congenital nevocytic nevi and malignant melanomas. J Am Acad Dermatol 1979; 1:123â€“30. https://doi.org/10.1016/S0190-9622(79)70009-0
Recio A1, SÃ¡nchez-Moya AI2, FÃ©lix V3, Campos Y4. Congenital Melanocytic Nevus Syndrome: A Case Series. Actas Dermosifiliogr. 2017. pii: S0001-7310(16)30371-4. https://doi.org/10.1016/j.ad.2016.07.025
MartÃn-Carrasco P, Bernabeu-Wittel J, Dominguez-Cruz J, Zulueta Dorado T, Conejo-Mir Sanchez J. "Sky Full of Stars" Pattern: Dermoscopic Findings in a Desmoplastic Giant Congenital Melanocytic Nevus.Pediatr Dermatol. 2017. https://doi.org/10.1111/pde.13099
How to Cite